tiprankstipranks
Arrowhead Pharmaceuticals Inc Unsponsored Brazilian Depositary Receipt Repr 0.125 Sh (BR:A2RR34)
:A2RR34
Brazil Market
A2RR34
Arrowhead Pharmaceuticals Inc Unsponsored Brazilian Depositary Receipt Repr 0.125 Sh
RESEARCH TOOLSreports

Arrowhead Pharmaceuticals Inc Unsponsored Brazilian Depositary Receipt Repr 0.125 Sh (A2RR34) Price & Analysis

― Followers

A2RR34 Stock Chart & Stats

R$55.60
R$1.58(2.92%)
―
--
Day’s Range― - ―
52-Week RangeR$9.24 - R$59.95
Previous CloseN/A
VolumeN/A
Average Volume (3M)477.00
Market Cap
R$60.52B
Enterprise ValueR$40.91K
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta0.46
Next Earnings
Nov 30, 2026
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding140,857,030
10 Day Avg. Volume462
30 Day Avg. Volume477
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A

Arrowhead Pharmaceuticals Inc Unsponsored Brazilian Depositary Receipt Repr 0.125 Sh News

Arrowhead price target raised to $104 from $98 at Stifel
Arrowhead price target raised to $104 from $98 at Stifel
Stifel raised the firm’s price target on Arrowhead (ARWR) to $104 from $98 and keeps a Buy rating...
10h ago
ARWR
Arrowhead reports Q3 EPS ($1.36), consensus ($1.23)
Arrowhead reports Q3 EPS ($1.36), consensus ($1.23)
Reports Q3 revenue $75.25M, consensus $44.01M. The company said, “The recent period for Arrowhead (ARWR) included transformational events...
1d ago
ARWR
Arrowhead acquires FDA priority review voucher
Arrowhead acquires FDA priority review voucher
Arrowhead (ARWR) Pharmaceuticals announced that it has signed an agreement with an undisclosed third party to acquire a...
1d ago
ARWR
Arrowhead price target raised to $123 from $101 at B. Riley
Arrowhead price target raised to $123 from $101 at B. Riley
B. Riley raised the firm’s price target on Arrowhead (ARWR) to $123 from $101 and keeps a Buy...
6d ago
ARWR
Arrowhead completes enrollment in Phase 3 YOSEMITE trial
Arrowhead completes enrollment in Phase 3 YOSEMITE trial
Arrowhead (ARWR) Pharmaceuticals announced that it has completed enrollment in the global Phase 3 YOSEMITE clinical trial of...
9d ago
ARWR
Arrowhead price target raised to $115 from $100 at H.C. Wainwright
Arrowhead price target raised to $115 from $100 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Arrowhead (ARWR) to $115 from $100 and keeps a Buy...
9d ago
ARWR
Arrowhead price target raised to $120 from $100 at Morgan Stanley
Arrowhead price target raised to $120 from $100 at Morgan Stanley
Morgan Stanley raised the firm’s price target on Arrowhead (ARWR) to $120 from $100 and keeps an Overweight...
13d ago
ARWR
Arrowhead price target raised to $126 from $110 at Piper Sandler
Arrowhead price target raised to $126 from $110 at Piper Sandler
Piper Sandler analyst Edward Tenthoff raised the firm’s price target on Arrowhead (ARWR) to $126 from $110 and...
13d ago
ARWR
Arrowhead price target raised to $115 from $90 at Chardan
Arrowhead price target raised to $115 from $90 at Chardan
Chardan analyst Keay Nakae raised the firm’s price target on Arrowhead (ARWR) to $115 from $90 and keeps...
14d ago
ARWR
Midday Fly By: AT&T reports Q2 beat, AMD invests $5B in Anthropic
Midday Fly By: AT&T reports Q2 beat, AMD invests $5B in Anthropic
The major averages were mixed near noon as traders take a cautious approach ahead of key earnings reports...
14d ago
T
PM
Arrowhead: Buy Rating Reiterated as Redemplo Momentum Builds and Pipeline Catalysts Support Unchanged $120 Price Target
Arrowhead: Buy Rating Reiterated as Redemplo Momentum Builds and Pipeline Catalysts Support Unchanged $120 Price Target
Arrowhead Pharmaceuticals, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Michael Ulz from...
7h ago
ARWR
Arrowhead: Strong Phase III Plozasiran Data and Priority Review Voucher Drive Accelerated Path to Market and $3B Global Sales Outlook, Supporting Buy Rating
Arrowhead: Strong Phase III Plozasiran Data and Priority Review Voucher Drive Accelerated Path to Market and $3B Global Sales Outlook, Supporting Buy Rating
TD Cowen analyst Joseph Thome has maintained their bullish stance on ARWR stock, giving a Buy rating yesterday....
14h ago
ARWR

A2RR34 FAQ

What was Arrowhead Pharmaceuticals Inc Unsponsored Brazilian Depositary Receipt Repr 0.125 Sh’s price range in the past 12 months?
Arrowhead Pharmaceuticals Inc Unsponsored Brazilian Depositary Receipt Repr 0.125 Sh lowest stock price was R$9.24 and its highest was R$59.95 in the past 12 months.
    What is Arrowhead Pharmaceuticals Inc Unsponsored Brazilian Depositary Receipt Repr 0.125 Sh’s market cap?
    Arrowhead Pharmaceuticals Inc Unsponsored Brazilian Depositary Receipt Repr 0.125 Sh’s market cap is R$60.52B.
      When is Arrowhead Pharmaceuticals Inc Unsponsored Brazilian Depositary Receipt Repr 0.125 Sh’s upcoming earnings report date?
      Arrowhead Pharmaceuticals Inc Unsponsored Brazilian Depositary Receipt Repr 0.125 Sh’s upcoming earnings report date is Nov 30, 2026 which is in 117 days.
        How were Arrowhead Pharmaceuticals Inc Unsponsored Brazilian Depositary Receipt Repr 0.125 Sh’s earnings last quarter?
        Currently, no data Available
        Is Arrowhead Pharmaceuticals Inc Unsponsored Brazilian Depositary Receipt Repr 0.125 Sh overvalued?
        According to Wall Street analysts Arrowhead Pharmaceuticals Inc Unsponsored Brazilian Depositary Receipt Repr 0.125 Sh’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does Arrowhead Pharmaceuticals Inc Unsponsored Brazilian Depositary Receipt Repr 0.125 Sh pay dividends?
          Arrowhead Pharmaceuticals Inc Unsponsored Brazilian Depositary Receipt Repr 0.125 Sh does not currently pay dividends.
          What is Arrowhead Pharmaceuticals Inc Unsponsored Brazilian Depositary Receipt Repr 0.125 Sh’s EPS estimate?
          Arrowhead Pharmaceuticals Inc Unsponsored Brazilian Depositary Receipt Repr 0.125 Sh’s EPS estimate for its next earnings report is not yet available.
          How many shares outstanding does Arrowhead Pharmaceuticals Inc Unsponsored Brazilian Depositary Receipt Repr 0.125 Sh have?
          Arrowhead Pharmaceuticals Inc Unsponsored Brazilian Depositary Receipt Repr 0.125 Sh has 140,857,030 shares outstanding.
            What happened to Arrowhead Pharmaceuticals Inc Unsponsored Brazilian Depositary Receipt Repr 0.125 Sh’s price movement after its last earnings report?
            Currently, no data Available
            Which hedge fund is a major shareholder of Arrowhead Pharmaceuticals Inc Unsponsored Brazilian Depositary Receipt Repr 0.125 Sh?
            Currently, no hedge funds are holding shares in BR:A2RR34
            What is the TipRanks Smart Score and how is it calculated?
            Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

              Arrowhead Pharmaceuticals Inc Unsponsored Brazilian Depositary Receipt Repr 0.125 Sh (A2RR34) Earnings & Revenues

              Historic Earnings Reports
              Similar Stocks
              Company
              Price & Change
              Follow
              B1AX34
              Baxter International Inc. Shs Unsponsored Brazilian Depositary Receipt Repr 1/2 Sh
              ―
              ―
              B1MR34
              Biomarin Pharmaceutical Inc. Shs Unsponsored Brazilian Depositary Receipt Repr 0.5 Sh
              ―
              ―
              R1DY34
              Dr Reddy'S Laboratories Ltd ADR Unsponsored Brazilian Depositary Receipt Repr 0.16666667 ADR
              ―
              ―
              R2GE34
              Repligen Corporation Shs Unsponsored Brazilian Depositary Receipt Repr 0.033333 Sh
              ―
              ―
              T1CH34
              Bio-Techne Corporation Unsponsored Brazilian Depository Receipt Repr 0.033333333 Sh
              ―
              ―
              Compare BR:A2RR34 Stocks >
              Popular Stocks